Additional Information

Description

Skyrizi 600 mg Sdv 10 mL Sd is a monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn’s disease in adults. It is designed for patients who require systemic therapy or phototherapy, providing targeted immune modulation. Skyrizi specifically inhibits interleukin-23 (IL-23), a cytokine involved in inflammatory processes associated with these conditions.

This formulation consists of 600 mg/10 mL (60 mg/mL) in a single-dose vial for intravenous administration. The intravenous route ensures rapid bioavailability, allowing for efficient disease control. Skyrizi is typically used as part of a long-term treatment regimen, reducing inflammation and alleviating symptoms such as plaque formation, joint pain, and gastrointestinal distress.

The therapy is administered under medical supervision, with dosing schedules tailored based on the patient’s condition. In plaque psoriasis and psoriatic arthritis, Skyrizi helps improve skin clearance and joint function, while in Crohn’s disease, it reduces intestinal inflammation and improves overall digestive health.